The present study aims to compare the changes of cardiovascular biomarkers and antioxidants during sedation by xylazine, detomidine, medetomidine, and dexmedetomidine in goats. This is experimental, crossover Latin square, randomized, blinded study. A total of 10 healthy (5 males and 5 females) goats aged 6 ± 1 months and weighing 15 ± 2 kg were used. Animals were assigned to five intravenous (IV) treatments: control (normal saline, 5 mL); XYL, xylazine (100 μg kg −1 ); DET, detomidine (50 μg kg −1 ); MED, medetomidine (20 μg kg −1 ); and DEX, dexmedetomidine (5 μg kg −1 ). Cardiac troponin I (cTnI), homocysteine (Hcy), lactate dehydrogenase (LDH), creatine kinase isoenzyme MB (CK-MB), superoxide dismutase (SOD), and glutathione peroxidase (GPx) were measured before (baseline), 2 h (T2), and 24 h (T24) after drug administration. cTnI was significantly higher in treatments α 2 -adrenergic agonists than control at T24. There were no significant differences in cTnI between different α 2 -adrenergic agonists at all-time points. No significant differences were observed in Hcy, LDH, CK-MB, SOD, and GPx at different times in each treatment or between treatments. In conclusion, IV administration of xylazine (100 μg kg −1 ), detomidine (50 μg kg −1 ), medetomidine (20 μg kg −1 ), and dexmedetomidine (5 μg kg − ) showed cardiac side effects after 24 h in goats. These results suggest that usage of α 2 -adrenergic agonists in goats should be administered with caution, especially in goats with cardiovascular problems.